Dr. Grentzmann has more than 15 years of experience in conducting and directing research in drug discovery, translational and molecular biology as well as data-integration in respiratory, inflammation and infectious diseases.  

Dr. Grentzmann has also had responsibilities spanning the establishment and running of expression profiling platforms, as well as the initiation and management of pharmaco-omics projects from both clinical and pharmacological studies, including study protocols, site selection, ethics, contracts, and IP.  Prior to teaming with CHA, Dr. Grentzmann was the director of Biochemistry and Genoprofiling at Altana Pharma in Waltham MA.  Before joining Altana, he spent 5 years at Parke-Davis (now Pfizer), where he held a number of positions in the area of translational biology.